Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Oncolytics Biotech ( (TSE:ONC) ) just unveiled an update.
On May 14, 2025, Oncolytics Biotech reported its first-quarter financial results and clinical progress, highlighting the promising potential of pelareorep in treating various cancers. Recent studies have shown encouraging results, particularly in anal and pancreatic cancers, with pelareorep demonstrating significant clinical benefits and a favorable safety profile. The company has secured a $20 million share purchase agreement to support ongoing clinical development and aims to reach key milestones with a projected cash runway through the third quarter of 2025.
The most recent analyst rating on (TSE:ONC) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the TSE:ONC Stock Forecast page.
Spark’s Take on TSE:ONC Stock
According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.
Oncolytics Biotech faces significant financial challenges with persistent operational losses and reliance on external funding. Although technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The valuation reflects the speculative nature of biotech investments, with no revenue and negative P/E. Recent earnings call and corporate events offer potential upside through strategic developments but are overshadowed by leadership transitions and market value concerns. Overall, the stock remains speculative with potential upside contingent on successful clinical outcomes.
To see Spark’s full report on TSE:ONC stock, click here.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on the development of immunotherapies for oncology. The company’s primary product, pelareorep, is an oncolytic virus designed to stimulate the immune system to target and destroy cancer cells. Oncolytics is particularly focused on challenging cancer types such as breast, pancreatic, and anal cancers.
Average Trading Volume: 71,806
Technical Sentiment Signal: Sell
Current Market Cap: C$63.95M
See more insights into ONC stock on TipRanks’ Stock Analysis page.